Authors
Loading...
Systematic review shows MVP has a prevalence of 5.4% in athletes, suggesting tailored surveillance for high-risk groups.
Sonaglioni et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: